FDA grants EUA to Molnarz’s molnupiravir COVID-19 drug

FILE PHOTO: FDA Director-General Eric Domingo. Photo courtesy: screenshot from media forum

MANILA, Philippines — The Food and Drug Administration (FDA) has authorized the emergency use of Molnarz’s molnupiravir, a drug indicated for the treatment of COVID-19, in the country.

“Sa ngayon po, mayroon tayong isang binigyan na ng EUA (emergency use authorization), ito po ‘yung molnupiravir na ang kanyang brand name ay Molnarz,” FDA director general Undersecretary Eric Domingo said during Thursday’s Laging Handa briefing.

(As of now, we granted a EUA to molnupiravir which brand name is Molnarz.)

“Ito pong Molnarz ‘yung pinaka-unang nag-apply at so far nakapag-comply po du’n sa ating mga requirements ng safety, efficacy, and quality,” he continued.

(Molnarz is the first to apply and so far, they complied with our requirements of safety, efficacy, and quality.)

According to Domingo, Molnarz’s molnupiravir is indicated to treat mild to moderate COVID-19.

The drug could be used by adults 18 years old and above, but it is not recommended for women with childbearing potential, pregnant, and lactating.

The drug comes in a 200-milligram capsule. Four capsules should be given every 12 hours for five days to an eligible COVID-19 patient.

“It should be given as soon as possible after diagnosis at dapat po (should be) within the first five days after the onset of symptoms,” said Domingo.

KGA